Population Health June 26, 2025
Save the Planet to Save Our Hearts (From Microplastics) June 26, 2025
We’ve all cut down on plastic straws to save the sea turtles, but what about ourselves? A recent AHA study suggests there could be a link between ocean microplastic levels and cardiovascular disease in U.S. coastal counties, adding to a concerning trend of microplastics and CV risk.
Surgeries & Interventions June 23, 2025
Edwards’ Evoque Might Have More Adverse Events Than Previously Known June 23, 2025
Over a year after becoming the first FDA-approved transcatheter tricuspid valve replacement system, a new JACC study suggests Edwards Lifesciences’ Evoque TTVR system might have some risks that regulators hadn’t previously considered.
Cardiac Imaging June 19, 2025
New AI-driven Tool Aids in Mitral Valve Assessment June 19, 2025
A new tool, Automated 3D Color Flow Quantification (3D Auto CFQ), removes the reliance on assumptions when quantifying mitral regurgitation and replaces it with a reliable and robust, AI-driven method that delivers precise measurement of mitral valve regurgitant volume (RVol) regardless of orifice shape and size.
Cardiology Business June 19, 2025
Lilly Buys Verve, Bringing Gene Editing Mainstream June 19, 2025
Gene editing for heart disease just got a major boost as Eli Lilly acquired Verve Therapeutics and its one-dose cholesterol drugs for up to $1.3B, marking a new path for Verve’s therapies to go mainstream.
Cardiac Imaging June 16, 2025
Beyond Hardware: Is AI the Answer to Making Cardiac Imaging More Accessible? June 16, 2025
Cardiac imaging has traditionally improved through hardware advances, enabling the speed needed for high-quality images. However, hardware is rapidly reaching its physical limitations in suppressing cardiac motion and represents a large financial investment.
Cardiology Pharmaceuticals June 16, 2025
No Need to Discontinue Abelacimab Pre-Procedure June 16, 2025
A new analysis of AZALEA-TIMI 71 suggests Anthos Therapeutics’ abelacimab is capable of reducing major bleeding in patients with AFib undergoing invasive procedures.
Cardiology Pharmaceuticals June 12, 2025
Pharmacologic Preconditioning to Improve Outcomes in Patients Undergoing Cardiac Surgery June 12, 2025
The majority of patients undergoing cardiac surgery, especially those on cardiopulmonary bypass (CPB), experience post-operative complications such as new-onset atrial fibrillation (POAF) and acute kidney injury (AKI), largely driven by oxidative stress and inflammation.
Cardiology Pharmaceuticals June 12, 2025
FDA Approves a New BP Triple Polypill June 12, 2025
Bringing a more effective BP therapy to the U.S. market, the FDA approved George Medicines’ triple therapy polypill called Widaplik for patients with hypertension, making it the first of its kind to go to market in the U.S.
Surgeries & Interventions June 9, 2025
Contrast Use During PCI on the Decline June 9, 2025
New ACC registry data suggests interventional cardiologists are using less contrast for PCI procedures in the cath lab which helps reduce post-PCI acute kidney injury risks, but a deeper look tells us there’s still room for improvement.
Cardiology Pharmaceuticals June 5, 2025
Regeneron & Hansoh’s GLP-1 Deal June 5, 2025
Just a few weeks after the full results of SURMOUNT-5 crowned Eli Lilly’s GLP-1/GIP tirzepatide king of the GLP-1s, Regeneron announced it will pay Hansoh Pharma $80M upfront and up to $1.93B in milestone payments for its Phase 3-stage GLP-1/GIP drug, HS-20094.
Cardiology Pharmaceuticals June 2, 2025
Deeper Answers from the ABYSS Trial June 2, 2025
Diving deeper into the ABYSS trial, a new sub-analysis suggests that patients with MI and preserved LVEF who stop taking their beta-blockers experience significant rises in heart rate and BP, potentially increasing their risk of adverse events.
Cardiology Business May 29, 2025
Boston Scientific Bows Out on TAVR May 29, 2025
Marking its departure from the TAVR market, Boston Scientific officially discontinued sales of its Acurate neo2 and Acurate Prime TAVR systems and will no longer seek approval from the FDA or other regulatory agencies.
Surgeries & Interventions May 22, 2025
Navitor Versus Sapien 3 Ultra: Different in the Details May 22, 2025
One year data from the NAVULTRA study published in JACC suggests that Edwards’ Sapien 3 Ultra and Abbott’s Navitor intra-annular TAVR valves have similar short-term clinical outcomes, with a few key differences.
Cardiology Pharmaceuticals May 19, 2025
Wegovy Rapidly Lowers MACE Risk May 19, 2025
Getting us closer to understanding GLP-1s’ heart benefits, a post hoc analysis of the SELECT trial suggests that Novo Nordisk’s Wegovy (semaglutide) significantly reduces a patient’s MACE risk in just three months of treatment.
Cardiology Pharmaceuticals May 15, 2025
Tirzepatide Beats Semaglutide in Weight Loss May 15, 2025
Has a king of the GLP-1s finally been crowned? Full results from the SURMOUNT-5 trial published in NEJM seem to suggest that Eli Lilly’s tirzepatide (Zepbound/Mounjarno) could be better than Novo Nordisk’s semaglutide (Wegovy/Ozempic).
Cardiology Testing May 12, 2025
Predicting ASCVD With Calprotectin May 12, 2025
Knowing which biomarkers to look for is critical to diagnosing and preventing ASCVD, and a new JAMA study suggests calprotectin could be the key to catching ASCVD early.
Cardiology Pharmaceuticals May 8, 2025
Obicetrapib Puts on a Show May 8, 2025
Results from NewAmsterdam Pharma’s Phase 3 BROADWAY and TANDEM trials suggest that obicetrapib could be an effective LDL-C lowering treatment, both on its own or combined with another drug.
Cardiology Pharmaceuticals May 8, 2025
Marea Makes Progress on MAR001 May 8, 2025
Marea Therapeutics presented positive data from the Phase 2a clinical trial of its fat-targeting monoclonal antibody, MAR001, that could help address lipid and metabolic drivers of ASCVD.
Surgeries & Interventions May 5, 2025
FDA Approves TAVR for Asymptomatic AS May 5, 2025
TAVR will officially be an option for asymptomatic patients with severe aortic stenosis following the FDA’s approval of Edwards Lifesciences’ SAPIEN 3 platform for the patient group.